Literature DB >> 3943016

Leukoplakia-associated multiple carcinomas in patients with tongue carcinoma.

H Shibuya, T Amagasa, K Seto, K Ishibashi, J Horiuchi, S Suzuki.   

Abstract

A series of 522 patients with a diagnosis of squamous cell carcinoma or carcinoma in situ of the tongue were reviewed and followed. Leukoplakia was found in 88 of these patients before and after the diagnosis of tongue carcinoma. A high incidence of multiple carcinomas in the oral cavity and pharynx (116 times greater than expected) was encountered in tongue carcinoma patients. The observed incidence of multiple oral carcinomas in the group with tongue carcinoma with leukoplakia was five times greater than that of the subjects without leukoplakia. The incidence of secondary esophageal carcinomas was also high, 12 times greater than the statistical expection. However, there was no increased occurrence of secondary esophageal carcinomas in the patients with leukoplakia.

Entities:  

Mesh:

Year:  1986        PMID: 3943016     DOI: 10.1002/1097-0142(19860215)57:4<843::aid-cncr2820570426>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Current status and perspectives of brachytherapy for head and neck cancer.

Authors:  Hitoshi Shibuya
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

2.  Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL.

Authors:  Sayako Oota; Hitoshi Shibuya; Ryo-ichi Yoshimura; Hiroshi Watanabe; Masahiko Miura
Journal:  Radiat Oncol       Date:  2006-07-12       Impact factor: 3.481

3.  Long-term follow-up of oral epithelial dysplasia: A hospital based cross-sectional study.

Authors:  Mohamed Abdullah Jaber; Essra Mohamed Elameen
Journal:  J Dent Sci       Date:  2020-05-01       Impact factor: 2.080

Review 4.  Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  Cancers (Basel)       Date:  2017-08-31       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.